Tommi Jaakkola

Tommi Jaakkola

Auto-generated profile, based on publicly available information

Tommi Jaakkola

Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, MA, USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2023 in Nature
Verified
Journal Article
Open access
PDF file
JWJoseph L. Watson
Joseph L. Watson
DJDavid Juergens
David Juergens
NBNathaniel R. Bennett
Nathaniel R. Bennett
BTBrian L. Trippe
Brian L. Trippe
JYJason Yim
Jason Yim
DBDavid Baker
David Baker
There has been considerable recent progress in designing new proteins using deep-learning methods1–9. Despite this progress, a general deep-learning framework for protein design that enables solution of a wide range of design challenges, including de novo binder design and design of higher-order symmetric architectures, has yet to be described. Diffusion models10,11 have had considerable success in image and language generative modelling but limited success when applied to protein modelling, probably due to the complexity of protein backbone geometry and sequence–structure relationships. Here we show that by fine-tuning the RoseTTAFold structure prediction network on protein structure denoising tasks, we obtain a generative model of protein backbones that achieves outstanding performance on unconditional and topology-constrained protein monomer design, protein binder design, symmetric oligomer design, enzyme active site scaffolding and symmetric motif scaffolding for therapeutic and metal-binding protein design. We demonstrate the power and generality of the method, called RoseTTAFold diffusion (RFdiffusion), by experimentally characterizing the structures and functions of hundreds of designed symmetric assemblies, metal-binding proteins and protein binders. The accuracy of RFdiffusion is confirmed by the cryogenic electron microscopy structure of a designed binder in complex with influenza haemagglutinin that is nearly identical to the design model. In a manner analogous to networks that produce images from user-specified inputs, RFdiffusion enables the design of diverse functional proteins from simple molecular specifications.

18 June 2025 in bioRxiv
Verified
Preprint
Open access
SPSaro Passaro
Saro Passaro
GCGabriele Corso
Gabriele Corso
JWJeremy Wohlwend
Jeremy Wohlwend
MRMateo Reveiz
Mateo Reveiz
STStephan Thaler
Stephan Thaler
RBRegina Barzilay
Regina Barzilay
Accurately modeling biomolecular interactions is a central challenge in modern biology. While recent advances, such as AlphaFold3 and Boltz-1, have substantially improved our ability to predict biomolecular complex structures, these models still fall short in predicting binding affinity, a critical property underlying molecular function and therapeutic efficacy. Here, we present Boltz-2, a new structural biology foundation model that exhibits strong performance for both structure and affinity prediction. Boltz-2 introduces controllability features including experimental method conditioning, distance constraints, and multi-chain template integration for structure prediction, and is, to our knowledge, the first AI model to approach the performance of free-energy perturbation (FEP) methods in estimating small molecule–protein binding affinity. Crucially, it achieves strong correlation with experimental readouts on many benchmarks, while being at least 1000 × more computationally efficient than FEP. By coupling Boltz-2 with a generative model for small molecules, we demonstrate an effective workflow to find diverse, synthesizable, high-affinity binders, as estimated by absolute FEP simulations on the TYK2 target. To foster broad adoption and further innovation at the intersection of machine learning and biology, we are releasing Boltz-2 weights, inference, and training code 1 under a permissive open license, providing a robust and extensible foundation for both academic and industrial research.

20 November 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
JWJeremy Wohlwend
Jeremy Wohlwend
GCGabriele Corso
Gabriele Corso
SPSaro Passaro
Saro Passaro
NGNoah Getz
Noah Getz
MRMateo Reveiz
Mateo Reveiz
RBRegina Barzilay
Regina Barzilay
Understanding biomolecular interactions is fundamental to advancing fields like drug discovery and protein design. In this paper, we introduce B oltz -1, an open-source deep learning model incorporating innovations in model architecture, speed optimization, and data processing achieving A lpha F old 3-level accuracy in predicting the 3D structures of biomolecular complexes. B oltz -1 demonstrates a performance on-par with state-of-the-art commercial models on a range of diverse benchmarks, setting a new benchmark for commercially accessible tools in structural biology. Further, we push the boundary of capabilities of these models with B oltz-steering , a new inference time steering technique that is able to fix hallucinations and non-physical predictions from the models. By releasing the training and inference code, model weights, datasets, and benchmarks under the MIT open license, we aim to foster global collaboration, accelerate discoveries, and provide a robust platform for advancing biomolecular modeling.

25 May 2023 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
GLGary Liu
Gary Liu
DCDenise B. Catacutan
Denise B. Catacutan
KRKhushi Rathod
Khushi Rathod
KSKyle Swanson
Kyle Swanson
WJWengong Jin
Wengong Jin
JSJonathan M. Stokes
Jonathan M. Stokes

3 April 2020 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
TSThomas J. Struble
Thomas J. Struble
JAJuan C. Alvarez
Juan C. Alvarez
SBScott P. Brown
Scott P. Brown
MCMilan Chytil
Milan Chytil
JCJustin Cisar
Justin Cisar
KJKlavs F. Jensen
Klavs F. Jensen
Artificial intelligence and machine learning have demonstrated their potential role in predictive chemistry and synthetic planning of small molecules; there are at least a few reports of companies employing in silico synthetic planning into their overall approach to accessing target molecules. A data-driven synthesis planning program is one component being developed and evaluated by the Machine Learning for Pharmaceutical Discovery and Synthesis (MLPDS) consortium, comprising MIT and 13 chemical and pharmaceutical company members. Together, we wrote this perspective to share how we think predictive models can be integrated into medicinal chemistry synthesis workflows, how they are currently used within MLPDS member companies, and the outlook for this field.

22 December 2023 in Science
Verified
Journal Article
Closed access
BKBrent A. Koscher
Brent A. Koscher
RCRichard B. Canty
Richard B. Canty
MMMatthew McDonald
Matthew McDonald
KGKevin P. Greenman
Kevin P. Greenman
CMCharles J. McGill
Charles J. McGill
KJKlavs F. Jensen
Klavs F. Jensen
A closed-loop, autonomous molecular discovery platform driven by integrated machine learning tools was developed to accelerate the design of molecules with desired properties. We demonstrated two case studies on dye-like molecules, targeting absorption wavelength, lipophilicity, and photooxidative stability. In the first study, the platform experimentally realized 294 unreported molecules across three automatic iterations of molecular design-make-test-analyze cycles while exploring the structure-function space of four rarely reported scaffolds. In each iteration, the property prediction models that guided exploration learned the structure-property space of diverse scaffold derivatives, which were realized with multistep syntheses and a variety of reactions. The second study exploited property models trained on the explored chemical space and previously reported molecules to discover nine top-performing molecules within a lightly explored structure-property space.